Launched at the beginning of 2013, the European Lead Factory is a pan-European drug discovery project, and a flagship open innovation resource for academia, public organisations, large pharma companies and SMEs. TI Pharma runs the Programme Office for an international consortium of 30 partners, with funding from IMI and in-kind contribution from various partners, offering facilities that are open to non-contractual partners. Academics and SMEs enjoy access to an 'industry-like' discovery platform - one that encourages active participation.

The European Lead Factory is currently actively seeking high quality biology targets. The goal is to provide target contributors with ultra-high throughput screening and a list of high quality hit compounds, and opportunities for collaboration. It means substantial cost savings and a very productive exchange of ideas.

New chemistry scaffolds are also being sought. A 300,000-strong compound collection has already been contributed by EFPIA consortium members, and a key project goal is to add a further 200,000 innovative compounds, carefully selected from academia and SMEs for novelty, drug-like properties, diversity and synthetic tractability. This will result in a Joint European Compound Collection, that will be used to screen against biology targets.

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.

For more information, please contact info@tipharma.com or call +31 71 332 2030 or visit the European Lead Factory website at http://www.europeanleadfactory.eu/.

“TI Pharma has developed frameworks in which academia and industry bring their ideas together and they work on the best ideas together.”

Share this page: